Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer
Ontology highlight
ABSTRACT: This is a phase I/II study of the combination of Guadecitabine (SGI-110) and previously treated metastatic colorectal cancer patients. This study will be conducted in two components. First, patients will be enrolled in a phase I study of SGI-110 combined with irinotecan in a standard 3+3 design. After the maximum tolerated dose (MTD) is determined, patients will subsequently be enrolled in a 2:1 randomized phase II study of SGI-110 and irinotecan versus the standard of care regorafenib or Lonsurf (TAS-102).
DISEASE(S): Colorectal Cancer Recurrent,Previously Treated Metastatic Colorectal Cancer,Colorectal Neoplasms
PROVIDER: 2148118 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA